Partnership Expands Access to Clinically Critical Genetic Testing in Support of Leading Research Programs

NEW HAVEN, CT and PRINCETON, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc., a clinical-stage life sciences company focused on unmet medical needs and high-quality genomic and biomarker testing solutions, today announced that its wholly-owned subsidiary, DiamiR Biosciences, has entered into an agreement to provide Progressive Medical Research (PMR) with Apolipoprotein E (APOE) genotyping services in support of their ongoing clinical and translational research programs.

APOE genotyping is widely recognized as one of the key genetic markers with significant clinical implications, particularly in studies related to Alzheimer’s disease, cardiovascular health, and lipid metabolism. By leveraging Niki BioSolutions’ College of American Pathologists (CAP) and New York State Clinical Laboratory Evaluation Program (CLEP) approved testing platform and laboratory infrastructure, Progressive Medical Research will be positioned to integrate high-quality, validated genetic data directly into its clinical trials workflows.

The collaboration reflects both organizations’ shared commitment to advancing precision medicine and generating actionable genetic insights that can inform clinical research and therapeutic development in Alzheimer’s disease.